IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
CD79B Gene Mutation
Chinese Academy of Medical Sciencesmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the CD79B Gene Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(+)-VINCRISTINE Henan Cancer Hospital | Phase 2 | CCC |
Cyclophosphamide Henan Cancer Hospital | Phase 2 | CCC |
Zanubrutinib Henan Cancer Hospital | Phase 2 | CCC |
Ibrutinib Chinese Academy of Medical Sciences | Phase 2 | CCC |
Epirubicin Henan Cancer Hospital | Phase 2 | CCC |
PREDNISONE TABLETS Henan Cancer Hospital | Phase 2 | CCC |
Inno-206 Henan Cancer Hospital | Phase 2 | CCC |
VINCRISTINE SULFATE Henan Cancer Hospital | Phase 2 | CCC |
Same molecule, other indications
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →